Cargando…
The effects of recombinant human growth hormone therapy on thyroid function in pediatric patients with growth hormone deficiency
BACKGROUND: Recombinant human growth hormone (rhGH) was approved for the therapy of pediatric patients with growth hormone deficiency (GHD) by the Food and Drug Administration (FDA) of the United States in 1985. This study aims to evaluate the effects of rhGH therapy on thyroid function in pediatric...
Autores principales: | Yao, Qian, Zheng, Dong, Liang, Yan, Hou, Ling, Ying, Yan-Qin, Luo, Xiao-Ping, Wu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107847/ https://www.ncbi.nlm.nih.gov/pubmed/34012834 http://dx.doi.org/10.21037/tp-20-401 |
Ejemplares similares
-
Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
por: Hou, Ling, et al.
Publicado: (2015) -
PEGylated Recombinant Human Growth Hormone Jintrolong(®) Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients
por: Wu, Wei, et al.
Publicado: (2022) -
Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies
por: Luo, Xiaoping, et al.
Publicado: (2017) -
Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients
por: Kucharska, Anna Małgorzata, et al.
Publicado: (2021) -
Effect of Vitamin D Combined with Recombinant Human Growth Hormone in Children with Growth Hormone Deficiency
por: Wang, Pingping, et al.
Publicado: (2022)